Inventiva (NASDAQ:IVA) Price Target Raised to $13.00 at Guggenheim

Inventiva (NASDAQ:IVA) had its target price lifted by Guggenheim from $9.00 to $13.00 in a report released on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, Piper Sandler assumed coverage on Inventiva in a research report on Wednesday, August 27th. They set an “overweight” rating and a $26.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Inventiva has an average rating of “Moderate Buy” and a consensus price target of $13.67.

Inventiva Price Performance

NASDAQ:IVA opened at $5.26 on Tuesday. Inventiva has a 52 week low of $1.53 and a 52 week high of $6.50. The firm has a 50 day moving average of $3.75 and a 200 day moving average of $3.41.

Hedge Funds Weigh In On Inventiva

An institutional investor recently bought a new position in Inventiva stock. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 10,715 shares of the company’s stock, valued at approximately $32,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.